BNR Burning Rock Biotech Ltd: Earnings per share for the last twelve months

Serving as a valuation tool, the EPS (TTM) chart for Burning Rock Biotech (BNR) shows a figure of 51.40. The business relies on the implementation of liquid biopsy in medical centers for rapid tumor diagnostics. Meanwhile, management faces pressure from local laws and PRC risks, despite their digital literacy. Simultaneously, Burning Rock Biotech (BNR) is maximizing its development in NGS sequencing for the ultra-early detection of pathologies.
BNR (brbiotech.com): analytical breakdowns and indicator data

The implementation of Burning Rock Biotech (BNR) liquid biopsy standards across Chinese oncology clinics directly impacts earnings per share dynamics. By analyzing EPS YoY volatility over the last 12 months, investors can assess net profit growth rates on a rolling basis, which helps determine the business's margin of safety under negative scenarios and avoid purchasing the asset at local peaks.